9999999997-12-007828.txt : 20120417 9999999997-12-007828.hdr.sgml : 20120417 20120415135729 ACCESSION NUMBER: 9999999997-12-007828 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20120417 DATE AS OF CHANGE: 20120415 20120417 20120415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chelsea Therapeutics International, Ltd. CENTRAL INDEX KEY: 0001333763 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 203174202 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 000-51462 FILM NUMBER: 12759761 BUSINESS ADDRESS: STREET 1: 3530 TORINGDON WAY STREET 2: SUITE 200 CITY: CHARLOTTE STATE: NC ZIP: 28277 BUSINESS PHONE: 704-341-1516 MAIL ADDRESS: STREET 1: 3530 TORINGDON WAY STREET 2: SUITE 200 CITY: CHARLOTTE STATE: NC ZIP: 28277 CT ORDER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``*.7`94P`C$+`P<#%LP(#`@-C$R(#7!E+T]B:E-T;3X^5."%`<)["U16[W=N[S&IKG'Z7"]XVJ\S8!9O?3%AN]G8Y'+KP;W/XJQ:[SZ;8K.UV"=G-\:[!E+$;%+J30=!2!V.Q\U^,8BB M!`8!5VX^[@;G,EZ2=Z*KHGS^D!>5Z6!F?L%]4^GZ(_EFNC*,/,Y!]GDV&#?E M>IJ3/[.ML:LMFS5MI4LR/?J6E.OHB]5EL1K5F](`9YDUU8/[G6,_'\9BRVVQ MLTW+OI^,0H..=6[W5+03RH@HN&I?T M5?<10BB6/?VPV%#>/AGJ[-">^_3:;KN%C#C@B;B7IP=]01"`C\&(?[GG1TG9 M/_'&L8)8"%`JH1LD*46A/0U#'Z>20V84Q>3S7^$'^7)\/?\,73[&HR2KTV7_ M+2_10EU&<1^/]7%"9UF^%\'X'$&NWH;@7^D+7Z$OD>^#[ZW<27[!G13_P=WQ MX![P_IF\2^VXW7/FB+2>'"3.[YSW%5ZLB=O_D2F,)^*0T`O2CH2&.K[ M.F4.6;[\?]".&=$JN8>VXG$8D<:A/9HE97=A%`A`9V0O^;?9JM;.X'YP_W]/JQ,^(B> M!E'B\7CS" MK>/&6/KC;)4L5[>8W>I&I^4S&H;8AGXWL[LY,[N7UPO<,;N#Y'$Q2^YQ8M'" MC1-^41'K@5&-+`2L*@J8A\O]<,+`A?G-;RSV,(S:X9_E2_[YZ*,?1$6$1A$* M4TN2\$AU[[SJL*_:@@V.RR+N(^4^+K\\%JWJ=28(>6M:'],@.&E]:`(B($VW M?7%B?%"VK<@A+2$]'`J9Z3#0E;FHX=&)4`&=@Q>$`GI6Z)C'LEFX=1G4XDZYXBGR>D<3RB>ZMGML%(ZIBDCJM:8JG=[LUBBR/9]"AX MYU([$Y-EP3OH?W1I(7=2-)`VYUW,JI<7VX](B6A(/QH$:J&M,_4\-G8GR[34 M$WV.68:J/E570F3Q6=]WT+;-]J(7)-@(!`M4-T;`6!C3G+VC%P M>*)K.J?`.=N0[<;9D-#D/J4>YR=R&.)SW=R-,];Y7,N?LE'A\(AYI3J.C`N/ M1?N#J_MZ7WVH:G/^C2Y:P!X!U)["(O0(_D%5[G`LTEJ@@$T9LD0RE56K&'WH MMBC(X@UR:=)'!_!M^MZ`N^8-:;*B:@2*AP*"D%5UCDHLWL9:2UI_F,'DA'?O MDD#!Y4C]:0-,CPDF!^BHO(X=-KC%#RP0WDP4J'Y,Z+H9*#RZ#0Z M%CL$'E0&K<2ZB$`EH0L<1"VKW.38'$2F1)!_[C>6$4_LS M`OW2VA,XVB@P)Q2)P\*0*S3KJGO>VZ]6U4]A;&VKS!9E8=;1BQ#BH%:YOV,X7-8NT M,]N-I=EH;T/K^LS6CGZA,Q/'.QZ8]8/AI"%DT:_8I.:FNLK,.I.0/;!1S^+/ MJ6/@HB_R_*UFL%LDH_\$&`"NO.H9#0IE;F1S=')E86T-96YD;V)J#3$@,"!O M8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+T9I7!E+T]B:E-T;3X^R`(L'Z+G9V``$&`(V%"#<-"F5N9'-T7!E+UA-3"]4>7!E+TUE=&%D871A/CYS M=')E86T-"CP_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ MDY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#0N,BXQ+6,P-#,@-3(N M,S&UL;G,Z>&UP/2)H='1P.B\O M;G,N861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AM<#I#&UP.D-R96%T;W)4 M;V]L/@H@("`@("`@("`\>&UP.DUO9&EF>41A=&4^,C`Q,BTP-"TQ-50Q,SHU M-3HS.2TP-#HP,#PO>&UP.DUO9&EF>41A=&4^"B`@("`@("`@(#QX;7`Z0W)E M871E1&%T93XR,#$R+3`T+3$U5#$S.C4U.C,Y+3`T.C`P/"]X;7`Z0W)E871E M1&%T93X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S M8W)I<'1I;VX@&UL.FQA;F<](G@M9&5F875L="(^36EC&UP34TZ26YS=&%N8V5)1#YU=6ED.C=C,6$R,F,S M+6-C,6(M-#8P92TY83!F+3)E,&0X8C4Q9#%A-CPO>&UP34TZ26YS=&%N8V5) M1#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#POJ'5!:DZ@Y*D%!56;/&!Q)[^MYW:,CK4'+966A3(J M-R8O4UDD4B8_:XOZTT3^'8VP(<#%T;*58(06FF<=VO^3GM"NDR/63(2W,4+K ME^A#<`2E,$+!E0U^MOA9KIQG9Q^#8YW?W`7O$08D"RGHO=PIL;$C87'B=?T5 M8`">C$!9#0IE;F1S=')E86T-96YD;V)J#34@,"!O8FH-/#PO1&5C;V1E4&%R M;7,\/"]#;VQU;6YS(#0O4')E9&EC=&]R(#$R/CXO1FEL=&5R+T9L871E1&5C M;V1E+TE$6SQ&,$$V,T,R,C0R13=&.35"-T$S-T,R14(S-C(W1$1"-#X\13$U M.$5&-C0U045&.$8T13@V,CDW13(U,S="1$-%-C4^72]);F9O(#D@,"!2+TQE M;F=T:"`T."]2;V]T(#$Q(#`@4B]3:7IE(#$P+U1Y<&4O6%)E9B]76S$@,B`Q M73X^